1. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. SEER Cancer Statistics Review, 1975-2016;2019 ASI 4474-35. National Cancer Institute. Bethesda, MD: 2019 April.
2. Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips K, Mooij TM, Roos-Blom M, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017 Jun 20;317(23):2402–16. https://doi.org/10.1001/jama.2017.7112.
3. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. The New England Journal of Medicine. 1997 May 15;336(20):1401–8. https://doi.org/10.1056/NEJM199705153362001.
4. Tung N, Lin NU, Kidd J, Allen BA, Singh N, Wenstrup RJ, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 May 1;34(13):1460–8. https://doi.org/10.1200/JCO.2015.65.0747.
5. Markham MJ, Moore K. Management of ovarian cancer associated with BRCA and other genetic mutations [Internet]. [cited 11/21/19]. Available from: https://www.uptodate.com/contents/management-of-ovarian-cancer-associated-with-brca-and-other-genetic-mutations?search=ovarian%20cancer%20BRCA&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.